Pfizer Explores $2B Drug Portfolio Sale

Feb 03, 2017


Pfizer Inc. is considering the sale of a group of treatments in cardiology, urology and primary care to raise cash and streamline its portfolio, according to a Bloomberg article.

The drugs are said to have sales of more than $700 million, and sellers could pay more than $2 billion for the portfolio, says sources familiar with the matter. Pfizer is reportedly working with financial advisers at JPMorgan Chase & Co., which is at a preliminary stage, the people said.

Read the Bloomberg story

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments